Not medical advice. Semaglutide is a research compound. This guide does not provide dosing, diagnosis, therapy recommendations, or claims about effects in humans.
Semaglutide is a GLP-1 receptor agonist studied heavily for incretin biology, glucose regulation, and appetite circuits in research animals and clinical trial literature (outside our sales jurisdiction).
One-paragraph overview from our research datasheet — still scientific, but faster to read than the full mechanism list below.
Semaglutide, long-acting GLP-1 receptor agonist with 94% human GLP-1 homology, C18 fatty diacid albumin binding, and 7-day pharmacokinetic half-life.
Peer-reviewed literature typically discusses Semaglutide in specific experimental settings. The points below reflect how the scientific community frames this compound—not as health claims, but as the research questions being asked.
Research vs. personal use: Literature describes experiments in controlled lab and animal models. This is distinct from any real-world use; our products are for laboratory research only.
Metabolic peptides in this category are investigated for appetite signalling, incretin pathways, and energy balance in research models. Literature emphasises mechanisms rather than lifestyle advice.
Our datasheet lists mechanistic themes observed in preclinical work. These are research endpoints, not health claims. They help scientists understand and compare pathways.
Storage requirements: Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. Use within the validated stability window for the specific batch and formulation. · Learn best practices in our detailed storage guide.
Research dosing context: Literature typically discusses 0.25–2.4 mg subcutaneously (dose escalation) · Once weekly subcutaneous injection · t½ ≈ 7 days (165–184 h); steady-state in 4–5 weeks; Vd ~12.5 L (SC); >99% albumin bound; SC bioavailability ~89%; oral bioavailability 0.4–1%; clearance ~0.035 L/h; ~3% excreted unchanged in urine. Metabolized via proteolytic cleavage and fatty acid β-oxidation; no CYP-mediated interactions.
Preparation steps: Follow our detailed reconstitution guide, use the calculator tool for volume confirmation, and always verify purity with the COA reading guide.
Semaglutide is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist — the peptide best known as the active ingredient in Novo Nordisk's Ozempic and Wegovy. Semaglutide is the research-grade form of this semaglutide peptide, supplied as a lyophilised powder strictly for in-vitro and preclinical laboratory research. It is NOT Ozempic or Wegovy, is not an approved medicine, and is not for human use.
In the research literature semaglutide binds and activates the GLP-1 receptor, which slows gastric emptying, acts on hypothalamic appetite centres, and enhances glucose-dependent insulin secretion. The fatty-acid/albumin modification extends its half-life to about a week. These are mechanisms described in published studies of the molecule, not human-use guidance — Semaglutide is supplied for research only.
It is the same active peptide (semaglutide), but it is NOT the same product. Ozempic and Wegovy are FDA-approved, prescription, sterile finished pharmaceuticals manufactured under cGMP. Semaglutide is an unapproved, research-grade lyophilised powder sold for laboratory research use only — not for human consumption, and not a substitute for any prescribed medication.
As an approved prescription medicine, semaglutide has been extensively studied in human trials under medical supervision. That clinical record does NOT extend to research-grade material: Semaglutide is unapproved, is not manufactured as a sterile human drug, and has no human safety assurances. New-U supplies it for laboratory research only and makes no human-use or safety claims.
Semaglutide shares 94% of its sequence with human GLP-1 but has three engineered modifications: an Aib substitution at position 8 that blocks degradation by DPP-IV, an Arg at position 34, and a C18 fatty diacid attached to Lys26. The fatty acid binds to albumin, extending half-life from ~2 minutes to ~7 days.
Semaglutide reaches meaningful GLP-1 receptor occupancy in the hypothalamus, where it directly suppresses appetite, while also slowing gastric emptying. The combined central and peripheral effects produce a much larger and more durable energy-balance shift than earlier GLP-1 agonists could achieve.
No. Semaglutide is supplied as a research-grade lyophilised powder for in-vitro and preclinical research only. It is not a licensed pharmaceutical product and is not a substitute for any prescribed medication.
Store the lyophilised powder in a freezer at −20 °C. After reconstitution with bacteriostatic water, refrigerate at 1-6 °C and protect from light. Avoid repeated warming and cooling cycles, as the fatty acid tail is sensitive to prolonged heat exposure.
In the published clinical literature on the reference drug (for example the STEP-1 extension study of semaglutide), discontinuing a GLP-1 receptor agonist is followed by the return of appetite signalling and gradual regain of much of the lost body weight over roughly a year, because the receptor stimulation that slowed gastric emptying and curbed appetite is withdrawn. Those observations come from trials of the approved medicines in human subjects — Semaglutide is an unapproved research-grade peptide supplied for laboratory research only and is not for human use.
No, and no. This article is educational only. We do not provide dosing, medical recommendations, or health claims. Our products are sold strictly for laboratory research, not for personal use of any kind.
Open the shop listing via “View product details.” There you will see batch specs, the Certificate of Analysis (COA), concentration, purity grade, and available SKUs with current pricing.
Other compounds researchers often read about alongside Semaglutide.
Primary literature and registries for Semaglutide, plus mainstream coverage of the peptide category. Research use only - not medical advice.
Databases & literature:
Peptides in the news:
Access concentration, batch info, variants, and current pricing on our shop.
Also known as: Semaglutide Acetate, GLP-1 Receptor Agonist